Chemotherapy regimen | No. of patients | No. of MSI-H | No. of MSI-L- | Recurrence /2ndCA |
---|---|---|---|---|
High conc. FEC a | 68 | 19 | 37 | 14 |
5-Floururacil 500 mg/m2 |  |  |  |  |
Epirubicin 90–100 mg/m2 |  |  |  |  |
Cyclophosphamide 600 mg/m2 |  |  |  |  |
Low conc. FEC a | 31 | 4 | 18 | 2 |
5-Floururacil 300–400 mg/m2 |  |  |  |  |
Epirubicin 50–75 mg/m2 |  |  |  |  |
Cyclophosphamide 400 mg/m2 |  |  |  |  |
AC b | 13 | 0 | 6 | 0 |
Adriamycin (Doxorubicin) 60 mg/m2 |  |  |  |  |
Cyclophosphamide 600 mg/m2 |  |  |  |  |
TC c | 3 | 0 | 2 | 0 |
Taxotere (Docetaxel) 75 mg/m2 |  |  |  |  |
Cyclophosphamide 600 mg/m2 |  |  |  |  |
PT d | 2 | 0 | 1 | 0 |
Carboplatin (Paraplatin) AUC 6 mg/ml/min |  |  |  |  |
Taxotere 175 mg/m2 |  |  |  |  |
TA e | 1 | 0 | 0 | 0 |
Taxotere 90 mg/m2 |  |  |  |  |
Avastin (Bevacizumab) 10 mg/kg |  |  |  |  |
TH f | 3 | 0 | 0 | 0 |
Taxotere 90 mg/m2 |  |  |  |  |
Herceptin (Trastuzumab) 4 mg/kg |  |  |  |  |
LT g | 1 | 0 | 0 | 0 |
Lapatinib (Tykerb) 1500 mg po |  |  |  |  |
Taxotere 175 mg/m2 |  |  |  |  |
TE h | 1 | 0 | 0 | 0 |
Epirubicin 75 mg/m2 |  |  |  |  |
Taxotere 200 mg/m2 |  |  |  |  |
Total | 123 | 23 | 64 | 16 |